Sacituzumab Govitecan for treating Patients with metastatic triple-negative Breast Cancer

被引:0
|
作者
Lorenz, Judith
机构
关键词
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
引用
收藏
页码:1271 / 1271
页数:1
相关论文
共 50 条
  • [1] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Hurvitz, S. A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Brufsky, A.
    Sardesai, S. D.
    Kalinsky, K.
    Zelnak, A. B.
    Weaver, R.
    Traina, T.
    Dalenc, F.
    Aftimos, P.
    Lynce, F.
    Diab, S.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V
    Ferrario, C.
    Schmid, P.
    Carey, L. A.
    Gianni, L.
    Piccart, M. J.
    Loibl, S.
    Goldenberg, D. M.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Rugo, H. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16): : 1529 - 1541
  • [2] Tackling metastatic triple-negative breast cancer with sacituzumab govitecan
    Schreiber, Anna R.
    Andress, Michelle
    Diamond, Jennifer R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1303 - 1311
  • [3] Sacituzumab govitecan in triple-negative breast cancer
    de Nonneville, Alexandre
    Goncalves, Anthony
    Mamessier, Emilie
    Bertucci, Francois
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (11)
  • [4] Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Mayer, I. A.
    Vahdat, L. T.
    Tolaney, S. M.
    Isakoff, S. J.
    Diamond, J. R.
    O'Shaughnessy, J.
    Moroose, R. L.
    Santin, A. D.
    Abramson, V. G.
    Shah, N. C.
    Rugo, H. S.
    Goldenberg, D. M.
    Sweidan, A. M.
    Iannone, R.
    Washkowitz, S.
    Sharkey, R. M.
    Wegener, W. A.
    Kalinsky, K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08): : 741 - 751
  • [5] Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer
    Ozaki, Yukinori
    Masuda, Jun
    Takano, Toshimi
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24): : 2382 - 2382
  • [6] Sacituzumab govitecan-hziy for triple-negative breast cancer
    Stirrups, Robert
    LANCET ONCOLOGY, 2019, 20 (04): : E194 - E194
  • [7] Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
    Maltoni, Roberta
    Bravaccini, Sara
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (07)
  • [8] Sacituzumab govitecan-a new therapy for patients with triple-negative breast cancer
    Pogoda, Katarzyna
    Jagiello-Gruszfeld, Agnieszka
    Niwinska, Anna
    Nowecki, Zbigniew
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (01): : 43 - 49
  • [9] Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors
    Sathe, Abhishek G.
    Singh, Indrajeet
    Singh, Pratap
    Diderichsen, Paul M.
    Wang, Xiaohui
    Chang, Peter
    Taqui, Atiya
    Phan, See
    Girish, Sandhya
    Othman, Ahmed A.
    CLINICAL PHARMACOKINETICS, 2024, 63 (05) : 669 - 681
  • [10] An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer
    Cheng, Shao-Xian
    Chen, Qiu-Chi
    Lin, Guo-He
    Han, Yan-Hong
    Wang, Bi-Cheng
    Dai, Yi
    Zhao, Yan-Xia
    MEDICINE, 2023, 102 (30) : E34486